Abstract

NF-κB signaling has been discovered for nearly 40 years. Initially, NF-κB signaling was identified as a pivotal pathway in mediating inflammatory responses. However, with extensive and in-depth investigations, researchers have discovered that its role can be expanded to a variety of signaling mechanisms, biological processes, human diseases, and treatment options. In this review, we first scrutinize the research process of NF-κB signaling, and summarize the composition, activation, and regulatory mechanism of NF-κB signaling. We investigate the interaction of NF-κB signaling with other important pathways, including PI3K/AKT, MAPK, JAK-STAT, TGF-β, Wnt, Notch, Hedgehog, and TLR signaling. The physiological and pathological states of NF-κB signaling, as well as its intricate involvement in inflammation, immune regulation, and tumor microenvironment, are also explicated. Additionally, we illustrate how NF-κB signaling is involved in a variety of human diseases, including cancers, inflammatory and autoimmune diseases, cardiovascular diseases, metabolic diseases, neurological diseases, and COVID-19. Further, we discuss the therapeutic approaches targeting NF-κB signaling, including IKK inhibitors, monoclonal antibodies, proteasome inhibitors, nuclear translocation inhibitors, DNA binding inhibitors, TKIs, non-coding RNAs, immunotherapy, and CAR-T. Finally, we provide an outlook for research in the field of NF-κB signaling. We hope to present a stereoscopic, comprehensive NF-κB signaling that will inform future research and clinical practice.

Details

Title
NF-κB in biology and targeted therapy: new insights and translational implications
Author
Guo, Qing 1 ; Jin, Yizi 1 ; Chen, Xinyu 2 ; Ye, Xiaomin 3 ; Shen, Xin 4 ; Lin, Mingxi 1 ; Zeng, Cheng 1 ; Zhou, Teng 1 ; Zhang, Jian 1 

 Fudan University Shanghai Cancer Center, Department of Medical Oncology, Shanghai, China (GRID:grid.452404.3) (ISNI:0000 0004 1808 0942); Fudan University, Department of Oncology, Shanghai Medical College, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443) 
 Shanghai Jiao Tong University, State Key Laboratory of Oncogenes and Related Genes, Renji-Med-X Stem Cell Research Center, Shanghai Cancer Institute & Department of Urology, Ren Ji Hospital, School of Medicine and School of Biomedical Engineering, Shanghai, PR China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293) 
 the First Affiliated Hospital of Sun Yat-Sen University, Department of Cardiology, Guangzhou, China (GRID:grid.412615.5) (ISNI:0000 0004 1803 6239) 
 Shanghai Jiao Tong University School of Medicine, Department of Neurology, Ruijin Hospital, Shanghai, China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293) 
Pages
53
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2934014723
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.